X
Supply constraint of Creon® 10000 Creon® 25000 (Pancreatin)
4th July 2024
As the marketing authorisation holder and distributor of Creon® in the UK, we were notified by our third-party manufacturing partner, Abbott, of a supply constraint of Creon® (pancreatin) in the UK.
This constrained supply is due to high global demand and reaching maximum manufacturing supply output.
Creon® is a biologic product with a natural variation of its raw material and is made using a complex manufacturing process. The complexity of the process means that the ability to increase manufacturing capacity in the short-term is limited.
There is a long-term strategic initiative between Viatris and Abbott to increase the supply output of Creon® at the manufacturing facility. This work has already begun with expected completion in 2026.
During this supply constraint, we hope to be able to supply approximately 90-95% of the average monthly demand for Creon® lipase units into the market each month, until this supply constraint is resolved.
If you require additional information or have any questions, please contact customer services on 01707 853100 or via email; productenquiries@viatris.co.uk. For medical enquiries please contact our medical information team on 01707 853 000 or via email; info.uk@viatris.co.uk.
UK-CRE-2024-00006 July 2024